The Cancer Drugs Fund (CDF) was initially set up as a temporary measure to pay for oncology drugs not recommended for routine NICE reimbursement, however, it’s been extended past the initial three years, had it’s budget increased, and is experiencing a growing demand for funding. This doesn’t sound temporary! CDF chair, Professor Peter Clark talks about undermining NICE, trying to bring the two organizations together, and what that means for the future here. (Source: PMLiVE, 1/20/14)
You are here: / / CDF Chair Regrets Undermining NICE – What Does This Mean For Future Reimbursements?